Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 10 of 10 publications.

Rebordosa C, Plana E, Rubino A, Aguado J, Martinez D, Lei A, Daoud S, Saigi-Morgui N, Perez-Gutthann S, Rivero-Ferrer E. Risk assessment of acute myocardial infarction and stroke associated with long-acting muscarinic antagonists, alone or in combination, versus long-acting beta2-agonists. Int J Chron Obstruct Pulmon Dis. 2022 Aug 2;17:1715-33. doi: 10.2147/COPD.S363997

Alvarez-Martin C, Ribera A, Marsal JR, Ariza-Sole A, Perez-Hoyos S, Oristrell G, Soriano-Colome T, Romaguera R, Pijoan JI, Lidon RM, Mauri J, Ferreira-Gonzalez I. Dynamics of emergency cardiovascular hospital admissions and in-hospital mortality during the COVID-19 pandemic: time series analysis and impact of socioeconomic factors. Front. Cardiovasc. Med. 2022 Apr 26. doi: 10.3389/fcvm.2022.827212

Rebordosa C, Plana E, Rubino A, Aguado J, Lei A, Daoud S, Saigi-Morgui N, Perez-Gutthann S, Rivero-Ferrer E. A cohort study to evaluate the risk of hospitalisation for congestive heart failure associated with the use of aclidinium and other chronic obstructive pulmonary disease medications in the UK Clinical Practice Research Datalink. Int J Chron Obstruct Pulmon Dis. 2021 May 31;16:1461-75. doi: 10.2147/COPD.S301624

Donohue IF, Bollu VK, Stull DE, Nelson LM, Williams VS, Stensland MD, Hanania NA. Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial. Int J Chron Obstruct Pulmon Dis. 2018 Feb 5;13:499-508.

Wilson MR, Patel JG, Coleman A, McDade CL, Stanford RH, Earnshaw SR. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model. Int J Chron Obstruct Pulmon Dis. 2017 Mar 24;2017(12):997-1008.

Schwab P, Dhamane AD, Hopson SD, Moretz C, Annavarapu S, Burslem K, Renda A, Kaila S. Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis. 2017 Feb 23;12:735-44. doi: 10.2147/COPD.S112256

Dhamane AD, Schwab P, Hopson S, Moretz C, Annavarapu S, Burslem K, Renda A, Kaila S. Association between adherence to medications for COPD and medications for other chronic conditions in COPD patients. Int J Chron Obstruct Pulmon Dis. 2016 Dec 22;12:115-22. doi: 10.2147/COPD.S114802

Tennis P, Chan KA, Curkendall SN, Li DK, Mines D, Peterson C, Andrews EB, Calingaert B, Chen HY, Deshpande G, Everage N, Holick CN, Meyer NM, Nkhoma ET, Quinn S, Rothman KJ, Esposito DB. Topiramate use during pregnancy and major congenital malformations in multiple populations. Birth Defects Res Part A Clin Mol Teratol. 2015 Apr;103(4):269-75. doi: 10.1002/bdra.23357.

Rycroft CE, Heyes A, Lanza L, Becker K. Epidemiology of chronic obstructive pulmonary disease: a literature review. Int J Chron Obstruct Pulmon Dis. 2012 Jul 1;7:457-94.

Dalal AA, Demuro-Mercon C, Lewis S, Nelson L, Gilligan T, McLeod L. Validation of alternate modes of administration of the lung function questionnaire (LFQ) in subjects with smoking history. Int J Chron Obstruct Pulmon Dis. 2010 Dec 1;5:425-34.